Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases
##plugins.themes.academic_pro.article.main##
Abstract
Background: Sickle cell disease is a serious illness by its complications. For the severe forms, three therapeutic options are actually allowed: transfusion therapy, hydroxyurea and bone marrow transplantation.
aim: To evaluate the contribution of hydroxyurea in the management of severe forms of sickle cell disease.
methods: It is a prospective study carried out a period of 11 years in “Centre National de Greffe de Moelle Osseuse” of Tunis. They were 65 patients divided into 38 homozygote forms and 27 double heterozygous composite S/β thalassemics. The mean age was 130 months. The failure criterion of the treatment was hospitalization duration more than 15 days/ patient / year or the occurrence of a severe complication of the disease.
results: The main indications of hydroxyurea were the prevention of the recidivism of an acute chest syndrome in 8 cases, iterative painful
crises, more than 3 events per year, in 53 cases and anemic forms of the disease in 4 cases. We have observed, a rapid and durable improvement in the clinical manifestations and a significant fall of the number of hospitalization days / patient/year from 25.2 days to 2.6 days (p<0.001). The treatment was well tolerated. The rates of foetal hemoglobin have significantly increased from 6.4 to 27.45 % (p<0.001), of hemoglobin from 7.6 to 9.4 g/dl(p<0.001), of the mean corpuscular volume from 80.3 to 99.1 fl (p<0.001), and a significant fall of the white blood cell rate from 15077 to 8170/mm3 (p<0.001), of polynuclear neutrophils from 8015 to 3509/mm3 (p<0.001), and reticulocytes from 693736 to 209837 /mm3(p<0.001) was observed.Ten patients were considered as treatment failure with a failure rate of 15.3%. The main failure etiology was represented with bad observance.
Conclusion: Hydroxyurea has a favored place in management of severe forms of sickle cell diseases of the child. Carefully used, with frequent monitoring does not have problems in short range but acceptance studies on the long term mast be undertaken.
aim: To evaluate the contribution of hydroxyurea in the management of severe forms of sickle cell disease.
methods: It is a prospective study carried out a period of 11 years in “Centre National de Greffe de Moelle Osseuse” of Tunis. They were 65 patients divided into 38 homozygote forms and 27 double heterozygous composite S/β thalassemics. The mean age was 130 months. The failure criterion of the treatment was hospitalization duration more than 15 days/ patient / year or the occurrence of a severe complication of the disease.
results: The main indications of hydroxyurea were the prevention of the recidivism of an acute chest syndrome in 8 cases, iterative painful
crises, more than 3 events per year, in 53 cases and anemic forms of the disease in 4 cases. We have observed, a rapid and durable improvement in the clinical manifestations and a significant fall of the number of hospitalization days / patient/year from 25.2 days to 2.6 days (p<0.001). The treatment was well tolerated. The rates of foetal hemoglobin have significantly increased from 6.4 to 27.45 % (p<0.001), of hemoglobin from 7.6 to 9.4 g/dl(p<0.001), of the mean corpuscular volume from 80.3 to 99.1 fl (p<0.001), and a significant fall of the white blood cell rate from 15077 to 8170/mm3 (p<0.001), of polynuclear neutrophils from 8015 to 3509/mm3 (p<0.001), and reticulocytes from 693736 to 209837 /mm3(p<0.001) was observed.Ten patients were considered as treatment failure with a failure rate of 15.3%. The main failure etiology was represented with bad observance.
Conclusion: Hydroxyurea has a favored place in management of severe forms of sickle cell diseases of the child. Carefully used, with frequent monitoring does not have problems in short range but acceptance studies on the long term mast be undertaken.
Keywords:
Sickle cell disease, hyroxyurea, child, acceptance##plugins.themes.academic_pro.article.details##
References
- Hankins JS, Ware RE, Rogers ZR et al. Long term hydroxyurea therapy for infants with sickle cell anemia: the Husoft extension study. Blood 2005;106:2269-75.
- Platt OS, Brambilla DJ, Rosse WF et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med. 1994; 330:1639-44.
- Russell E. Ware. How I use hydroxyurea to treat young patients with sickle cell anemia. Blood 2010;115:5300-11.
- Charache S, Terrin ML, Moore RD et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 1995;332:1317-22.
- Charache S, Barton FB, Moore RD et al. Hydroxyurea and sickle cell anemia. Medicine (Baltimore) 1996;75:300-26.
- Ferster A, Vermylen C, Cornu G et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 1996;88:1960-4.
- Ferster A, Tahriri P, Vermylen C et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 2001;97:3628-32.
- Voskaridou E, Christoulas D, Bilalis A et al. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-63.
- Gulbis B, Haberman D, Dufour D et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events: the Belgian experience. Blood 2005 105: 2685-90.
- De Montalembert M. Hydroxyurea treatment in patients affected with sickle cell anemia: Efficacy and safety. Transfusion Clinique et Biologique 2008;15:34-8.
- Maier-Redelsperger M, De Montalembert M, Flahault A et al. Fetal Hemoglobin and F-Cell Responses to Long-Term Hydroxyurea Treatment in Young Sickle Cell Patients. Blood 1998;91:4472-9.
- Kinney TR, Helms RW, O'Branski EE et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Blood 1999;94:1550-4.
- Voskaridou E, Kalotychou V, Loukopoulos D. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle cell ß-thalassaemia. Br J Haematol 1995;89:479-84.
- Zimmerman SA, Schultz WH, Ware RE et al. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-45.
- Wang WC, Wynn LW, Rogers ZR et al. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 2001;139:790-6.
- De Montalembert M, Brousse V, Elie C et al. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 2006;91:125-8.
- Vichinsky EP, Lubin BH. A cautionary note regarding hydroxyura in sickle cell disease. Blood 1994;83:1124-8.
- Venigalla P, Motwani B, Nallari A et al. A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection. Blood 2002;100:363-4.
- Ware RE, Eggleston B, Redding-Lallinger R et al. Predictors of fetal haemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-4.
- Ware RE, Eggleston B, Redding-Lallinger R et al. Predictors of fetal haemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 2002;99:10-14.
- Charache S, Dover GJ, Moyer MA et al. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 1987;69:109-16.
- Charache S, Dover GJ, Moore RD et al. Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555-65.